SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 222 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,406,477 | -35.6% | 196,100 | -29.8% | 0.01% | -33.3% |
| Q2 2023 | $8,398,764 | -25.1% | 279,400 | -9.8% | 0.02% | -27.6% |
| Q1 2023 | $11,220,431 | +45.6% | 309,700 | +43.4% | 0.03% | +31.8% |
| Q4 2022 | $7,704,720 | +133.9% | 216,000 | +122.0% | 0.02% | +120.0% |
| Q3 2022 | $3,294,000 | +695.7% | 97,300 | +580.4% | 0.01% | +900.0% |
| Q2 2022 | $414,000 | -58.3% | 14,300 | -53.4% | 0.00% | -66.7% |
| Q1 2022 | $992,000 | +52.6% | 30,700 | +37.7% | 0.00% | +50.0% |
| Q4 2021 | $650,000 | +90.6% | 22,300 | +74.2% | 0.00% | +100.0% |
| Q3 2021 | $341,000 | -87.2% | 12,800 | -85.3% | 0.00% | -85.7% |
| Q2 2021 | $2,673,000 | -56.1% | 86,800 | -62.7% | 0.01% | -58.8% |
| Q1 2021 | $6,095,000 | +69.2% | 232,800 | +62.6% | 0.02% | +70.0% |
| Q4 2020 | $3,603,000 | -28.8% | 143,200 | -41.0% | 0.01% | -28.6% |
| Q3 2020 | $5,058,000 | -48.8% | 242,700 | -41.7% | 0.01% | -51.7% |
| Q2 2020 | $9,885,000 | +44.7% | 416,200 | +9.6% | 0.03% | +11.5% |
| Q1 2020 | $6,833,000 | +122.3% | 379,800 | +193.1% | 0.03% | +271.4% |
| Q4 2019 | $3,074,000 | -13.9% | 129,600 | -0.2% | 0.01% | -22.2% |
| Q3 2019 | $3,570,000 | -67.2% | 129,900 | -60.5% | 0.01% | -66.7% |
| Q2 2019 | $10,893,000 | +33.9% | 329,200 | +41.8% | 0.03% | +28.6% |
| Q1 2019 | $8,136,000 | +1072.3% | 232,200 | +1901.7% | 0.02% | +950.0% |
| Q2 2018 | $694,000 | +116.2% | 11,600 | +65.7% | 0.00% | +100.0% |
| Q1 2018 | $321,000 | -59.5% | 7,000 | -62.0% | 0.00% | -66.7% |
| Q2 2017 | $793,000 | +39.1% | 18,400 | +1.1% | 0.00% | +50.0% |
| Q1 2017 | $570,000 | +26.1% | 18,200 | +1.7% | 0.00% | 0.0% |
| Q4 2016 | $452,000 | +12.7% | 17,900 | +10.5% | 0.00% | 0.0% |
| Q3 2016 | $401,000 | -9.3% | 16,200 | -55.7% | 0.00% | -33.3% |
| Q1 2015 | $442,000 | – | 36,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |